Re: We have to CHANGE the question from WHEN to WHY?
Dr.Erin Foff at the CTAD Investor Event (Transcript)
"When we look at the double-blind relapse rates, it’s again a bit hard to interpret these results given the small numbers and we really were not powered to look at this in any meaningful statistical way. So, the best we can do is just describe it. So, aside from frontotemporal dementia where we had only a single patient relapse and that patient happened to be on pimavanserin.
The take-home here is that the relapsed rates on pimavanserin were a little narrow and low overall in the individual groups ranging from 0 in the DLB population to about 16.7% in the vascular dementia patients, and the range in the group receiving placebo was broader and higher again ranging from 16.7% to about 67%, not taking that FTD group into consideration. The actual relapse rates themselves are shown below."
I got that from Seeking Alpha, I would suggest everyone carefully read the transcript